Indicate the presence of numerical data in the abstract (whether numerical data plays a key role in medical records), solely using the information from the abstract.

Ex Input:
Abstract: Release of prostaglandin E (PGE) was examined in leukocyte cultures from patients with definite MS who had had at least one recent exacerbation, others with chronic progressive or stable MS, and healthy controls. MS patients had higher baseline levels of PGE than did controls. Patients with active symptoms exhibited a sharp increase in PGE release early in or just before the onset of clinical symptoms. Levels dropped early in exacerbation immediately after the burst in PGE synthesis activity. Values gradually increased to control levels and then to preexacerbation levels. Similar rises and falls were not seen in stable MS. MS patients may have a circulating population of activated leukocytes that produce PGE.
Question: Does the abstract contain any numerical data?

Ex Output:
No

Ex Input:
Abstract: Several preclinical and clinical studies have documented that dose or dose intensity of chemotherapeutic agents are important factors for response of patients' tumors. This finding has prompted empiric trials of certain chemotherapeutic agents in high-dose or regional administration treatment regimens. The present study was performed to identify agents that would be particularly good candidates for high-dose or regional administration regimens against particular types of tumors. Using a human tumor cloning technique, we constructed dose in vitro response lines for ten different chemotherapeutic agents against seven different histologic types of malignancies. Slopes of the lines indicated the agents with the greatest increases of in vitro response per increment in dose of the agent. Tumors against which the agents gave the steepest dose response lines included lymphoma, head and neck cancer, ovarian cancer, and small-cell lung cancer, while the dose response lines for non-small-cell lung cancer, breast cancer, and colon cancer were quite flat. Suggestions for clinical trials based on these findings include the use of high-dose melphalan for patients with lymphoma, head and neck, and ovarian cancer; the use of mitoxantrone in high-dose regimens for patients with breast cancer; high-dose cisplatin regimens for patients with small-cell lung cancer; high-dose bleomycin regimens for patients with non-small-cell lung and head and neck cancer; and regional perfusion of liver metastases from colorectal cancer with cisplatin. Prospective testing of high-dose or regional administration regimens suggested by this new model should indicate its use for prediction of the best agent to use in high-dose regimens against a particular tumor type.
Question: Does the abstract contain any numerical data?

Ex Output:
No

Ex Input:
Abstract: Mucoceles of the sphenoid sinus are rare. Only occasional reports have appeared in the medical literature since they were first described by Berg in 1889. The sphenoid sinus lies deep within the skull at the crossroads of 13 sensitive structures. The presence of a sphenoid sinus mucocele may be accompanied by a wide variety of signs and symptoms depending upon which of these structures are involved. The majority of these lesions are initially misdiagnosed as malignancies leading to increased patient morbidity and possible mismanagement. We present two cases of sphenoid sinus mucoceles which presented with a variety of neurological signs and symptoms. The radiographic findings were felt to be consistent with skull base malignancies. The diagnosis was corrected only after surgical exploration of the sphenoid sinus revealed a mucocele.
Question: Does the abstract contain any numerical data?

Ex Output:
Yes